These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15908963)

  • 41. Differential recruitment of tetratricorpeptide repeat domain immunophilins to the mineralocorticoid receptor influences both heat-shock protein 90-dependent retrotransport and hormone-dependent transcriptional activity.
    Gallo LI; Ghini AA; Piwien Pilipuk G; Galigniana MD
    Biochemistry; 2007 Dec; 46(49):14044-57. PubMed ID: 18001136
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150).
    Takahashi M; Ubukata O; Homma T; Asoh Y; Honzumi M; Hayashi N; Saito K; Tsuruoka H; Aoki K; Hanzawa H
    FEBS Lett; 2020 May; 594(10):1615-1623. PubMed ID: 31991486
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Crystal structure of the human LRH-1 DBD-DNA complex reveals Ftz-F1 domain positioning is required for receptor activity.
    Solomon IH; Hager JM; Safi R; McDonnell DP; Redinbo MR; Ortlund EA
    J Mol Biol; 2005 Dec; 354(5):1091-102. PubMed ID: 16289203
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antagonism in the human mineralocorticoid receptor.
    Fagart J; Wurtz JM; Souque A; Hellal-Levy C; Moras D; Rafestin-Oblin ME
    EMBO J; 1998 Jun; 17(12):3317-25. PubMed ID: 9628869
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule.
    Fagart J; Hillisch A; Huyet J; Bärfacker L; Fay M; Pleiss U; Pook E; Schäfer S; Rafestin-Oblin ME; Kolkhof P
    J Biol Chem; 2010 Sep; 285(39):29932-40. PubMed ID: 20650892
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of amino acid determinants of dopamine 2 receptor synthetic agonist function.
    Al-Fulaij MA; Ren Y; Beinborn M; Kopin AS
    J Pharmacol Exp Ther; 2007 Apr; 321(1):298-307. PubMed ID: 17204745
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular dynamics of a biophysical model for beta2-adrenergic and G protein-coupled receptor activation.
    Rubenstein LA; Zauhar RJ; Lanzara RG
    J Mol Graph Model; 2006 Dec; 25(4):396-409. PubMed ID: 16574446
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Structures of the ligand-binding core of iGluR2 in complex with the agonists (R)- and (S)-2-amino-3-(4-hydroxy-1,2,5-thiadiazol-3-yl)propionic acid explain their unusual equipotency.
    Beich-Frandsen M; Pickering DS; Mirza O; Johansen TN; Greenwood J; Vestergaard B; Schousboe A; Gajhede M; Liljefors T; Kastrup JS
    J Med Chem; 2008 Mar; 51(5):1459-63. PubMed ID: 18269227
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A rearranging ligand enables allosteric control of catalytic activity in copper-containing nitrite reductase.
    Wijma HJ; Macpherson I; Alexandre M; Diederix RE; Canters GW; Murphy ME; Verbeet MP
    J Mol Biol; 2006 May; 358(4):1081-93. PubMed ID: 16574144
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Structural analysis of the evolution of steroid specificity in the mineralocorticoid and glucocorticoid receptors.
    Baker ME; Chandsawangbhuwana C; Ollikainen N
    BMC Evol Biol; 2007 Feb; 7():24. PubMed ID: 17306029
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structure of IRF-3 bound to the PRDIII-I regulatory element of the human interferon-beta enhancer.
    Escalante CR; Nistal-Villán E; Shen L; García-Sastre A; Aggarwal AK
    Mol Cell; 2007 Jun; 26(5):703-16. PubMed ID: 17560375
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The roles of Tyr(CD1) and Trp(G8) in Mycobacterium tuberculosis truncated hemoglobin O in ligand binding and on the heme distal site architecture.
    Ouellet H; Milani M; LaBarre M; Bolognesi M; Couture M; Guertin M
    Biochemistry; 2007 Oct; 46(41):11440-50. PubMed ID: 17887774
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular determinants in the second intracellular loop of the 5-hydroxytryptamine-1A receptor for G-protein coupling.
    Kushwaha N; Harwood SC; Wilson AM; Berger M; Tecott LH; Roth BL; Albert PR
    Mol Pharmacol; 2006 May; 69(5):1518-26. PubMed ID: 16410407
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An alternatively spliced rat mineralocorticoid receptor mRNA causing truncation of the steroid binding domain.
    Zhou MY; Gomez-Sanchez CE; Gomez-Sanchez EP
    Mol Cell Endocrinol; 2000 Jan; 159(1-2):125-31. PubMed ID: 10687858
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Crystal structure of an ancient protein: evolution by conformational epistasis.
    Ortlund EA; Bridgham JT; Redinbo MR; Thornton JW
    Science; 2007 Sep; 317(5844):1544-8. PubMed ID: 17702911
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mineralocorticoid receptors: evolutionary and pathophysiological considerations.
    Kassahn KS; Ragan MA; Funder JW
    Endocrinology; 2011 May; 152(5):1883-90. PubMed ID: 21343255
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ligand-induced conformational change in the human mineralocorticoid receptor occurs within its hetero-oligomeric structure.
    Couette B; Fagart J; Jalaguier S; Lombes M; Souque A; Rafestin-Oblin ME
    Biochem J; 1996 Apr; 315 ( Pt 2)(Pt 2):421-7. PubMed ID: 8615809
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Crystal structure of the mineralocorticoid receptor DNA binding domain in complex with DNA.
    Hudson WH; Youn C; Ortlund EA
    PLoS One; 2014; 9(9):e107000. PubMed ID: 25188500
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The binding mode of progesterone to its receptor deduced from molecular dynamics simulations.
    Mordasini T; Curioni A; Bursi R; Andreoni W
    Chembiochem; 2003 Mar; 4(2-3):155-61. PubMed ID: 12616628
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Human mineralocorticoid receptor interacts with actin under mineralocorticoid ligand modulation.
    Jalaguier S; Mornet D; Mesnier D; Léger JJ; Auzou G
    FEBS Lett; 1996 Apr; 384(2):112-6. PubMed ID: 8612804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.